Insmed - INSM Stock Forecast, Price & News

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Insmed Stock Performance

INSM opened at $26.75 on Friday. Insmed has a 12-month low of $16.41 and a 12-month high of $34.44. The stock's 50 day moving average price is $21.74 and its two-hundred day moving average price is $22.14. The company has a quick ratio of 5.34, a current ratio of 5.93 and a debt-to-equity ratio of 18.65.

Insmed (NASDAQ:INSM - Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.09. The business had revenue of $65.20 million for the quarter, compared to the consensus estimate of $58.92 million. Insmed had a negative net margin of 188.04% and a negative return on equity of 154.14%. Insmed's quarterly revenue was up 43.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.94) earnings per share. Sell-side analysts predict that Insmed will post -3.4 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Morgan Stanley cut their price target on Insmed from $46.00 to $41.00 and set an "overweight" rating on the stock in a report on Friday, July 15th. Credit Suisse Group lifted their target price on Insmed to $58.00 in a report on Tuesday. Finally, The Goldman Sachs Group cut their price objective on Insmed from $56.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $50.86.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 216,800 shares of the firm's stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $27.84, for a total value of $6,035,712.00. Following the completion of the sale, the chief executive officer now owns 256,716 shares in the company, valued at approximately $7,146,973.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 314,355 shares of company stock valued at $8,279,853 over the last three months. 4.63% of the stock is owned by corporate insiders.